ArticleAnnals of translational medicine2023

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma.

Takuya Maeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.